Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Iron Sucrose Injection in Healthy Subjects
NCT06622148Phase 1Completed
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iron sucrose in iron deficiency anemia (IDA) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 120 hours, Area Under the Curve to the Last Quantifiable Concentration at 120 hours and 1 more. Started Jun 2024; status: completed.
02
Drugs
iron sucrose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06622148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622148.